Detalles de la búsqueda
1.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Oncologist
; 2024 Feb 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38394384
2.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
N Engl J Med
; 383(11): 1040-1049, 2020 09 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32905676
3.
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med
; 380(13): 1235-1246, 2019 03 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-30763142
4.
The Correlation of Urethral Pressure Profilometry Data in Women with Different Types of Urinary Incontinence.
Urol Int
; 97(2): 218-23, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27074045
5.
Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial.
World J Urol
; 32(5): 1287-94, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24258313
6.
Prostate cancer trends in Latvia during 1990-2012: incidence, prevalence, mortality, and survival rates.
Medicina (Kaunas)
; 50(6): 313-7, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25541262
7.
Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck® as a diagnostic tool in upper urinary tract tumor.
Minerva Urol Nephrol
; 76(2): 195-202, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38498297
8.
Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial.
Eur J Cancer
; 192: 113258, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37660438
9.
A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer and skeletal metastases.
Eur J Cancer
; 181: 198-207, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36682096
10.
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
Eur Urol
; 83(3): 212-221, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36089529
11.
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.
Prostate Cancer Prostatic Dis
; 2023 Oct 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37884613
12.
Recurrent Prostate Cancer Diagnostics with 18F-PSMA-1007 PET/CT: A Systematic Review of the Current State.
Diagnostics (Basel)
; 12(12)2022 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36553183
13.
Epidemiologic, clinical, and molecular characteristics of hereditary prostate cancer in Latvia.
Medicina (Kaunas)
; 47(10): 579-85, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-22186123
14.
Diagnostic scope of 18F-PSMA-1007 PET/CT: comparison with multiparametric MRI and bone scintigraphy for the assessment of early prostate cancer recurrence.
Am J Nucl Med Mol Imaging
; 11(5): 395-405, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34754610
15.
Bladder cancer trends in Latvia during 1990-2017: incidence, mortality, and survival rates.
Cent European J Urol
; 74(1): 14-23, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33976911
16.
Diagnostic value of Xpert® Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer: an update.
Ther Adv Urol
; 13: 1756287221997183, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33747133
17.
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.
Eur J Cancer
; 154: 138-146, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34273811
18.
Can conventional urodynamic variables help to predict the necessity of overactive bladder symptomatic therapy in women after transobturator tape surgery?
Cent European J Urol
; 73(3): 315-320, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33133659
19.
The role of conventional urodynamic in diagnosing specific types of urinary incontinence in women.
Turk J Urol
; 46(2): 134-139, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32053097
20.
First-in-man Safety and Efficacy of the ClearRing Implant for the Treatment of Benign Prostatic Hyperplasia.
Eur Urol Focus
; 6(1): 131-136, 2020 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30293945